Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025-26 flu season in the US. As the world leader in flu vaccines, Sanofi had already begun its annual production of vaccines to ensure that robust supply is ready for the coming season. Strains selected by the FDA match those already used in production by the company to help protect eligible patients against flu and its potentially severe complications.
Sanofi plans to begin shipping flu vaccines this summer so that health systems, hospitals, pharmacies, physician practices, nursing homes and other facilities can begin administering vaccines at the onset of the next flu season.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.